Govt amends rules to debar pharma firms submitting fake or fabricated data

The Union health and family welfare ministry has recently amended the Drugs Rules, 1945, to debar pharmaceutical manufacturers from submitting fake or fabricated data for drug evaluation. Previously, applicants who submitted fabricated data faced rejection or license cancellation. However, the amendments now bar these entities from filing further applications with the regulatory authority, both at the state and central levels, for a specified period.

The ministry emphasized the importance of this step as a significant move towards enhancing the integrity and transparency of the drugs regulatory system. It also noted that the amendments complement existing enforcement provisions under the Drugs and Cosmetics Act, 1940. The ministry further explained that the licensing authority can now debar further applications by entities submitting fabricated data after issuing a show-cause notice and providing an appeal process.

The ministry reiterated that reliable scientific data is crucial for regulatory evaluation of drug quality, safety, and efficacy. By preventing the submission of fake or fabricated data, the government aims to deter misconduct, strengthen accountability, and ensure that drug approvals are backed by valid scientific evidence. The amendments align with the government's commitment to strengthening the regulatory framework based on global best practices.